This page contains a Flash digital edition of a book.
chromatography • spectroscopy 29


equilibrium dissociation constant determined by CG-MALS, KD


= 8nM, agrees well with the manufacturer’s data of KD


= 15nM,


as measured by ELISA. Furthermore, both thrombin and the antibody


exhibit no propensity for self- association, a finding that could not be evaluated by conventional ELISA or SPR.


Tus, CG-MALS as automated by


the Calypso system provides direct observation of multiple interactions in solution. By measuring the weight-average molar mass of the ensemble of molecules in solution, the presence of both the (1 Ab):


(1 Tr) and (1 Ab):(2 Tr) species can be tracked as a function of Ab and Tr concentration.


In addition, the monomeric state of both the antibody and antigen is confirmed. Tis simultaneous tracking of all affinities and stoichiometries present in solution makes CG-MALS unique among biophysical characterisation techniques and enables unambiguous quantification of macromolecular interactions.


Sophia Kenrick, Application Development Engineer, and Daniel Some, Principal Scientist, are with Wyatt Technology


Corporation, Santa Barbara, CA, USA. www.wyatt.com


NEW S-Live 1/2 page 11/20/06 12:27 PM Page 1


Fig. 3. Mole fraction of each species present during hetero-association gradient as a function of total thrombin and antibody concentrations.


News and reports on all the latest scientific discoveries, brought straight to your desktop


☛ Top stories of the day ☛ In depth reporting ☛ Latest product news ☛ Free e-mail newsletter


www.scientistlive.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52